“…The present status of clinical trials employing VACV against viral diseases is shown in Table 1. Other poxviruses that can be used as vaccine vectors belong to Avipoxvirus [44,45], Capripoxvirus [46], Leporipoxvirus [47], Parapoxvirus [48], and Suipoxvirus [49] genera. Abbreviations: Ad, adenovirus; Ad26, Ad serotype 26; Ad26.HPV16, Ad26 HPV16 vaccine; Ad26.HPV18, Ad26 HPV18 vaccine; Ad26.Mos.HIV, Ad26-mosaic-HIV vaccine; Ad26.Mos4.HIV, Ad26-mosaic 4-HIV vaccine; Ad26.ZEBOV, human Ad26 expressing the Ebola virus Mayinga variant gp; AIDS, acquired immune deficiency syndrome; ATI, analytical treatment interruption; bNAbs, broadly neutralizing HIV-1 antibodies; ChAd, Chimpanzee adenovirus; ChAd155, ChAd serotype 155; ChAd155-hIi-HBV, ChAd HBV vaccine; ChAd3-hliNSmut, ChAd3 encoding NSmut linked to hli; ChAdOx1, replication-deficient ChAd vector derived from isolate Y25; ChAdOx1.HTI, ChAdOx1 expressing HTI; ChAdV63, ChAd serotype 63; ChAdV63.HIVconsv, ChAdV63 expressing HIVconsv; CMV, cytomegalovirus; DNA.HTI, plasmid DNA expressing HTI; gp, glycoprotein; gp140 DP, gp140 drug product; GS-9620, vesatolimod; HBc, hepatitis B core antigen; HBc-HBs/AS01B-4, HBV vaccine; HBs, hepatitis B surface antigen; HBV, hepatitis B virus; HCT, hematopoietic cell transplantation; HIV, human immunodeficiency virus; HIV-1, HIV type 1; HIVcons, HIV conserved antigenic regions; hli, human invariant chain; HPV, human papillomavirus; HPV16/18, human papillomavirus type 16/18; HTI, HIVACAT T cell immunogen; IL-12, interleukin-12; M1, matrix protein; MenACWY, meningococcal ACWY-tetanus toxoid conjugate vaccine; MPXV, monkeypox virus; MVA, modified vaccinia virus Ankara; MVA.HIVconsv, MVA expressing HIVconsv; MVA.HPV16/18, MVA HPV16/18 vaccine; MVA.HTI, MVA expressing HTI; MVA.tHIVconsv3, MVA.tHIVconsv4, MVA-based T-cell vaccines expressing novel HIV-1 immunogens; MVA62B, MVA component encoding HIV-1 Gag, protease, reverse transcriptase, and envelope protein gp160; MVA-BN, MVA-Bavarian Nordic; MVA-BN-Filo, MVA-BN-Filo vector; MVA-HBV, MVA HBV vaccine; MVA-hliNSmut, MVA encoding NSmut linked to hli; MVA-mosaic, MVA mosaic HIV vaccine; MVA-NP + M1, MVA encoding NP and M1; NP, nucleoprotein; NSmut, HCV nonstructural immunogen; p24CE + p55 gag , DNA vaccines expressing p24CE and p55 gag immunogens; rVSV∆G-ZEBOV-GP, recombinant VSV-Zaire Ebola virus gp; TLR9, Toll-like receptor 9; VRC07, 10-1074, anti-HIV-1 bNAbs; VSV, vesicular stomatitis virus.…”